Ignite Creation Date:
2025-12-24 @ 3:02 PM
Ignite Modification Date:
2026-01-29 @ 1:43 PM
Study NCT ID:
NCT00095459
Status:
COMPLETED
Last Update Posted:
2019-12-17
First Post:
2004-11-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
Sponsor:
National Cancer Institute (NCI)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
050022
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None